IR
CDNA icon

Invictus RG’s CareDx CDNA Stock Holding History

Invictus RG’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,398
Closed -$485K – 28
2019
Q1 		$485K Buy
+15,398
New +$449K 1.86% 21

Other funds holding CDNA

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Invictus RG's CDNA Position: Q2 2019 in Review

Invictus RG sold out of CareDx (CDNA) in Q2 2019, closing a stake of 15,398 shares — an estimated $485K sold.

Invictus RG first reported a position in CDNA in Q1 2019 and held it in 1 quarter. The position peaked at $485K in Q1 2019. 182 funds tracked by Wall St. Rank hold CDNA as of Q2 2019.

  • Invictus RG reported no remaining CareDx position as of Q2 2019 after selling out during the quarter.
  • Invictus RG sold 15,398 CareDx shares in Q2 2019, an estimated $485K.
  • Invictus RG first reported a position in CareDx in Q1 2019 and held it in 1 quarter.
  • Invictus RG's CareDx position peaked at $485K in Q1 2019.
  • 182 funds tracked by Wall St. Rank held CareDx as of Q2 2019.

Based on Invictus RG's 13F filing for Q2 2019, filed 13 Aug 2019.